- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04353063
Muscle Wasting in Children and Adolescents With Cancer
Assessment and Management of Muscle Wasting in Children and Adolescents With Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Specific aims, year by year
The aim for Year 1 is as follows:
Aim 1: To explore parents' experience of caring for promoting a child's exercise among parents of children and adolescents with cancer.
The aims for Year 2 are as follows:
Aim 2-1: To examine the associations between the degree of muscle wasting and health-related variables (fatigue level, symptom distress level, physical activity involvement, dietary intake, and QoL) among children and adolescents with cancer.
Aim 2-2: To examine the trends of changes in muscle wasting and health-related variables (fatigue level, symptom distress level, physical activity involvement, dietary intake, and QoL) during the first 6 months of cancer treatment among children and adolescents with cancer.
- The aim for Year 3 is as follows:
Aim 3: To examine the effectiveness of a multidisciplinary approach with a personalized walking exercise program on changes in body composition and health-related variables (fatigue level, symptom distress level, subjective physical activity involvement, objective physical activity measurement, dietary intake, and QoL) among children and adolescents with cancer.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wei-Wen Wu, PhD
- Phone Number: 88422 886-2-23123456
- Email: weiwen@ntu.edu.tw
Study Contact Backup
- Name: Man-Rong Hsu, BSN
- Phone Number: 88422 886-2-23123456
- Email: mrhsu116135@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 10051
- Recruiting
- NTUH
-
Contact:
- Wei Wen Wu
- Phone Number: 88422 886-2-23123456
- Email: weiwen@ntu.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aim 1:(1) parents of children diagnosed with malignancies at 3-18 years old, (2) whose children have received cancer treatment for at least 6 months, (3) who are the main caregivers, and (4) who are willing to participate in the study.
- Aim 2-1:(1) children and adolescents diagnosed with malignancies at 3-18 years old, (2) who are previously or currently treated for cancer, and (3) who are willing to participate in the study. Two hundred patients will be recruited.
- Aim 2-2:(1) children and adolescents diagnosed with malignancies at 3-18 years old, (2) newly diagnosed with cancer within the past 1 month, and (3) willing to participate in the study. One hundred participants will be recruited.
- Aim 3:(1) children and adolescents aged 3-18 years old and are undergoing treatment, and (2) who are willing to participate in the study.
Exclusion Criteria:
-Aim 1-3: Children and adolescents are under poor physical or cognitive conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control group
The patients in the control group will not receive any walking exercise education until the 4-week intervention ends.
They will then receive the same education material ("How walking is beneficial to your health") and will be told about the benefits of walking.
|
|
Experimental: experimental group
Participants in the experimental group will also be educated on the general use of the ActiGraph through verbal and written information and will be asked to wear the ActiGraph during week 0 for 3 consecutive days.
The collected physical activity parameters will be the baseline data.Afterward, participants in the experimental group will be educated with the educational materials "How walking is beneficial to muscle mass and your health."
And then the ActiGraph will be collected by the research assistant in order to analyze the physical activity parameters, including time spent walking and walking steps.
A final assessment will be conducted at week 4.
The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4.
|
During the 4-week intervention, participants will be given stickers by the research assistant to increase their motivation to walk.
A sticker will be given once a participant reaches a daily walking-time goal.
The number of stickers participants receive depends on the number of days they reach their daily goals.
The stickers can be redeemed for the participant's choice of gift in the gift shelf of the ward or on a gift card.
A final assessment will be conducted at week 4.
The participant will be reminded that the ActiGraph and the post-test questionnaires will be picked up at the end of week 4
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographics
Time Frame: baseline
|
age, age at diagnosis, diagnosis, cancer recurrence or not, treatment status, gender, education, parents' education, height, and body weight.
|
baseline
|
Lab data
Time Frame: baseline
|
protein profile (albumin), lipid profile (TG, cholesterol, LDH, HDH), liver profile (GOT, GPT), CBC profile (HB, RBC, WBC/DC, platelet), renal profile (BUN, CRE), inflammation index (CRP), and sugar profile (Glucose-AC and HbA1C) at diagnosis and at study baseline.
|
baseline
|
Medication dosage
Time Frame: baseline
|
accumulated corticosteroid dosage, accumulated radiation dosage.
|
baseline
|
Cachexia assessment
Time Frame: baseline
|
This assessment includes weight loss grading and muscle power grading.
Weight loss grading uses a 5x5 matrix to grade the patient's level of cancer-associated weight loss.Grade 0 = complete paralysis; Grade 1 = flicker of contraction present; Grade 2 = active movement with gravity eliminated; Grade 3 = active movement against gravity; Grade 4 = active movement against gravity and some resistance described as poor, fair, or moderate strength; and Grade 5 = normal power.
|
baseline
|
Inbody S10
Time Frame: Week 0
|
The InBody S10 BIA device measures resistance at six frequencies (1, 5, 50, 250, 500, and 1000 KHz).
|
Week 0
|
Inbody S10
Time Frame: Week 4
|
The InBody S10 BIA device measures resistance at six frequencies (1, 5, 50, 250, 500, and 1000 KHz).
|
Week 4
|
Multidimensional Fatigue Scale (MFS):
Time Frame: week 4
|
MFS versions are designed for ages 5-18.
The parent proxy reports, which include children 2-4 years of age (toddler), are used to assess the parent's perception of their child's fatigue.
The instrument consists of 18 items.
Patients are assessed on how often a particular problem occurred in the past month by using a 5-point Likert scale from 0 to 4 and rescaled to 0-100, so that higher scores indicate fewer symptoms of fatigue.
|
week 4
|
Symptom Distress Scale (SDS)
Time Frame: Week 0(baseline)
|
The SDS is a 5-point mixed-response scale with 13 items that measure symptom distress.
Total scores range from 13 to 65; higher scores indicate more severe symptom distress during the past week.
|
Week 0(baseline)
|
Symptom Distress Scale (SDS)
Time Frame: week 1
|
The SDS is a 5-point mixed-response scale with 13 items that measure symptom distress.
Total scores range from 13 to 65; higher scores indicate more severe symptom distress during the past week.
|
week 1
|
Symptom Distress Scale (SDS)
Time Frame: week 2
|
The SDS is a 5-point mixed-response scale with 13 items that measure symptom distress.
Total scores range from 13 to 65; higher scores indicate more severe symptom distress during the past week.
|
week 2
|
Symptom Distress Scale (SDS)
Time Frame: week 3
|
The SDS is a 5-point mixed-response scale with 13 items that measure symptom distress.
Total scores range from 13 to 65; higher scores indicate more severe symptom distress during the past week.
|
week 3
|
Symptom Distress Scale (SDS)
Time Frame: week 4
|
The SDS is a 5-point mixed-response scale with 13 items that measure symptom distress.
Total scores range from 13 to 65; higher scores indicate more severe symptom distress during the past week.
|
week 4
|
Exercise Involvement Scale (EIS)
Time Frame: Week 0(baseline)
|
Exercise involvement is calculated by the equation: Exercise Involvement Score = exercise frequency x (exercise intensity + exercise duration).
The total score represents an individual's level of exercise involvement.
There are six graded response options, ranging from 1 (zero) to 6 (5 or more times a week).
A higher score indicates more frequent exercise during the past week.
|
Week 0(baseline)
|
Exercise Involvement Scale (EIS)
Time Frame: week 1
|
Exercise involvement is calculated by the equation: Exercise Involvement Score = exercise frequency x (exercise intensity + exercise duration).
The total score represents an individual's level of exercise involvement.
There are six graded response options, ranging from 1 (zero) to 6 (5 or more times a week).
A higher score indicates more frequent exercise during the past week.
|
week 1
|
Exercise Involvement Scale (EIS)
Time Frame: week 2
|
Exercise involvement is calculated by the equation: Exercise Involvement Score = exercise frequency x (exercise intensity + exercise duration).
The total score represents an individual's level of exercise involvement.
There are six graded response options, ranging from 1 (zero) to 6 (5 or more times a week).
A higher score indicates more frequent exercise during the past week.
|
week 2
|
Exercise Involvement Scale (EIS)
Time Frame: week 3
|
Exercise involvement is calculated by the equation: Exercise Involvement Score = exercise frequency x (exercise intensity + exercise duration).
The total score represents an individual's level of exercise involvement.
There are six graded response options, ranging from 1 (zero) to 6 (5 or more times a week).
A higher score indicates more frequent exercise during the past week.
|
week 3
|
Exercise Involvement Scale (EIS)
Time Frame: week 4
|
Exercise involvement is calculated by the equation: Exercise Involvement Score = exercise frequency x (exercise intensity + exercise duration).
The total score represents an individual's level of exercise involvement.
There are six graded response options, ranging from 1 (zero) to 6 (5 or more times a week).
A higher score indicates more frequent exercise during the past week.
|
week 4
|
Visual analogue scale for dietary intake (VAS-DI)
Time Frame: Week 0(baseline)
|
Patients are asked to answer the question: "If you consider that, at times when you are in good health, you eat 10 out of 10, how much do you currently eat on a scale from 0 to 10?" A response of 0 would mean eating "nothing at all" and 10 would be eating "as usual."
For patients who do not understand this question, the researcher helps by adding: "How do you currently eat at this moment: a quarter of the usual amount, half of the usual amount, or three-quarters of the usual amount?"
Patients tick a 100-mm line traced on paper to answer the inquiry "How much do you currently eat on a scale from 0 'nothing' (far left side of the line) to 10 'as usual' (far right side of the line)?"
The left extremity of the line is anchored by "I eat nothing at all" (0 cm), the middle by "I eat half the usual amount" (5 cm), and the right extremity by "I eat as usual" (10 cm).
|
Week 0(baseline)
|
Visual analogue scale for dietary intake (VAS-DI)
Time Frame: week 1
|
Patients are asked to answer the question: "If you consider that, at times when you are in good health, you eat 10 out of 10, how much do you currently eat on a scale from 0 to 10?" A response of 0 would mean eating "nothing at all" and 10 would be eating "as usual."
For patients who do not understand this question, the researcher helps by adding: "How do you currently eat at this moment: a quarter of the usual amount, half of the usual amount, or three-quarters of the usual amount?"
Patients tick a 100-mm line traced on paper to answer the inquiry "How much do you currently eat on a scale from 0 'nothing' (far left side of the line) to 10 'as usual' (far right side of the line)?"
The left extremity of the line is anchored by "I eat nothing at all" (0 cm), the middle by "I eat half the usual amount" (5 cm), and the right extremity by "I eat as usual" (10 cm).
|
week 1
|
Visual analogue scale for dietary intake (VAS-DI)
Time Frame: week 2
|
Patients are asked to answer the question: "If you consider that, at times when you are in good health, you eat 10 out of 10, how much do you currently eat on a scale from 0 to 10?" A response of 0 would mean eating "nothing at all" and 10 would be eating "as usual."
For patients who do not understand this question, the researcher helps by adding: "How do you currently eat at this moment: a quarter of the usual amount, half of the usual amount, or three-quarters of the usual amount?"
Patients tick a 100-mm line traced on paper to answer the inquiry "How much do you currently eat on a scale from 0 'nothing' (far left side of the line) to 10 'as usual' (far right side of the line)?"
The left extremity of the line is anchored by "I eat nothing at all" (0 cm), the middle by "I eat half the usual amount" (5 cm), and the right extremity by "I eat as usual" (10 cm).
|
week 2
|
Visual analogue scale for dietary intake (VAS-DI)
Time Frame: week 3
|
Patients are asked to answer the question: "If you consider that, at times when you are in good health, you eat 10 out of 10, how much do you currently eat on a scale from 0 to 10?" A response of 0 would mean eating "nothing at all" and 10 would be eating "as usual."
For patients who do not understand this question, the researcher helps by adding: "How do you currently eat at this moment: a quarter of the usual amount, half of the usual amount, or three-quarters of the usual amount?"
Patients tick a 100-mm line traced on paper to answer the inquiry "How much do you currently eat on a scale from 0 'nothing' (far left side of the line) to 10 'as usual' (far right side of the line)?"
The left extremity of the line is anchored by "I eat nothing at all" (0 cm), the middle by "I eat half the usual amount" (5 cm), and the right extremity by "I eat as usual" (10 cm).
|
week 3
|
Visual analogue scale for dietary intake (VAS-DI)
Time Frame: week 4
|
Patients are asked to answer the question: "If you consider that, at times when you are in good health, you eat 10 out of 10, how much do you currently eat on a scale from 0 to 10?" A response of 0 would mean eating "nothing at all" and 10 would be eating "as usual."
For patients who do not understand this question, the researcher helps by adding: "How do you currently eat at this moment: a quarter of the usual amount, half of the usual amount, or three-quarters of the usual amount?"
Patients tick a 100-mm line traced on paper to answer the inquiry "How much do you currently eat on a scale from 0 'nothing' (far left side of the line) to 10 'as usual' (far right side of the line)?"
The left extremity of the line is anchored by "I eat nothing at all" (0 cm), the middle by "I eat half the usual amount" (5 cm), and the right extremity by "I eat as usual" (10 cm).
|
week 4
|
PedsQL
Time Frame: Week 0(baseline)
|
The PedsQL Cancer Module is designed to measure pediatric cancer-specific health-related QoL in patients ages 2-18 years.
The scale consists of 27 items that address eight dimensions: pain and hurt, nausea, procedural anxiety, treatment anxiety, worry, cognitive problems, perceived physical appearance, and communication.
Items are rated on a 5-point scale
|
Week 0(baseline)
|
PedsQL
Time Frame: week 4
|
The PedsQL Cancer Module is designed to measure pediatric cancer-specific health-related QoL in patients ages 2-18 years.
The scale consists of 27 items that address eight dimensions: pain and hurt, nausea, procedural anxiety, treatment anxiety, worry, cognitive problems, perceived physical appearance, and communication.
Items are rated on a 5-point scale
|
week 4
|
ActiGraph
Time Frame: Week 0(baseline)
|
The ActiGraph GT3X accelerometer is a reliable and valid tool for assessing objective activity level, validated in participants ages 7-18 years.
It captures and records continuous raw acceleration data, which will be downloaded in 60-second epochs using ActiLife 6.13.3 software.
|
Week 0(baseline)
|
ActiGraph
Time Frame: week 1
|
The ActiGraph GT3X accelerometer is a reliable and valid tool for assessing objective activity level, validated in participants ages 7-18 years.
It captures and records continuous raw acceleration data, which will be downloaded in 60-second epochs using ActiLife 6.13.3 software.
|
week 1
|
ActiGraph
Time Frame: week 2
|
The ActiGraph GT3X accelerometer is a reliable and valid tool for assessing objective activity level, validated in participants ages 7-18 years.
It captures and records continuous raw acceleration data, which will be downloaded in 60-second epochs using ActiLife 6.13.3 software.
|
week 2
|
ActiGraph
Time Frame: week 3
|
The ActiGraph GT3X accelerometer is a reliable and valid tool for assessing objective activity level, validated in participants ages 7-18 years.
It captures and records continuous raw acceleration data, which will be downloaded in 60-second epochs using ActiLife 6.13.3 software.
|
week 3
|
ActiGraph
Time Frame: week 4
|
The ActiGraph GT3X accelerometer is a reliable and valid tool for assessing objective activity level, validated in participants ages 7-18 years.
It captures and records continuous raw acceleration data, which will be downloaded in 60-second epochs using ActiLife 6.13.3 software.
|
week 4
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wei-Wen Wu, PhD, National Taiwan University, College of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202001023RINA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Child Development
-
Yale UniversityRobinhood Foundation; Adelphi University; Docs for TotsCompletedSocial Skills | Child Behavior | Child Development | Infant DevelopmentUnited States
-
University of Southern CaliforniaSafe Water and AIDS Project (SWAP); Early Childhood Development Network for...RecruitingChild Behavior | Child Development | Language, ChildKenya
-
Windward Islands Research and Education FoundationGrand Challenges Canada; St. George's University; GRENCASECompletedDevelopment, Child | Behavior, Child | Neurocognition, ChildGrenada
-
London School of Hygiene and Tropical MedicineInternational Centre for Diarrhoeal Disease Research, Bangladesh; University... and other collaboratorsActive, not recruitingChild Development | Child Development DisorderBangladesh, Tanzania, Nepal
-
Children's Hospital of PhiladelphiaNational Institute on Minority Health and Health Disparities (NIMHD)Active, not recruitingDevelopment Delay | Development, ChildUnited States
-
The Hospital for Sick ChildrenAga Khan University; March of DimesCompletedChild Development | Child Mortality | Child Morbidity | Child BehaviourPakistan
-
University Hospital, RouenRecruitingChild Development | Child Mental Disorder | Adolescent Behavior | Child Behavior Disorders | Behavior, Child | Adolescent Development | Adolescent - Emotional Problem | Child Development DisorderFrance
-
O-KidiaRecruitingChild Development | Child Development DisorderFrance
-
International Centre for Diarrhoeal Disease Research...UnknownChild Behavior | Child DevelopmentBangladesh
-
Boston Medical CenterCenter for the Study of Social PolicyCompletedChild Abuse | Parenting | Child Development | Child Rearing | Child NeglectUnited States
Clinical Trials on Multidisciplinary care with a personalized care
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and Development; Dutch...Recruiting
-
Kaiser PermanenteGarfield Memorial FundCompletedLiver Failure | Acquired Immunodeficiency Syndrome | Stroke | Pneumonia | Diabetes Mellitus | Cancer | Pulmonary Disease, Chronic Obstructive | Respiratory Failure | Renal Failure | Dementia | Kidney Failure, Chronic | Coronary Arteriosclerosis | Cerebrovascular Accident | Failure to Thrive | Heart Failure, CongestiveUnited States
-
Maastricht University Medical CenterMaastricht UniversityCompleted
-
Federico II UniversityRecruiting
-
University Hospital, ToulouseRecruiting
-
Radboud University Medical CenterStichting Nuts Ohra; PorticusCompletedParkinson's DiseaseNetherlands
-
Azienda Usl di BolognaIRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS-Istituto...Completed
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanRecruitingChronic Kidney DiseaseTaiwan
-
Vastra Gotaland RegionRecruiting
-
Northwestern Health Sciences UniversityHealth Resources and Services Administration (HRSA); Berman Center for Outcomes...CompletedSub-Acute and Chronic Low Back PainUnited States